GCM
SGMT icon

Graham Capital Management’s Sagimet Biosciences SGMT Stock Holding History

Graham Capital Management’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-49,051
Closed -$336K – 1554
2025
Q3 		$336K Buy
+49,051
New +$398K 0.01% 810

Other funds holding SGMT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Graham Capital Management's SGMT Position: Q4 2025 in Review

Graham Capital Management sold out of Sagimet Biosciences (SGMT) in Q4 2025, closing a stake of 49,051 shares — an estimated $336K sold.

Graham Capital Management first reported a position in SGMT in Q3 2025 and held it in 1 quarter. The position peaked at $336K in Q3 2025. 86 funds tracked by Wall St. Rank hold SGMT as of Q4 2025.

  • Graham Capital Management reported no remaining Sagimet Biosciences position as of Q4 2025 after selling out during the quarter.
  • Graham Capital Management sold 49,051 Sagimet Biosciences shares in Q4 2025, an estimated $336K.
  • Graham Capital Management first reported a position in Sagimet Biosciences in Q3 2025 and held it in 1 quarter.
  • Graham Capital Management's Sagimet Biosciences position peaked at $336K in Q3 2025.
  • 86 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q4 2025.

Based on Graham Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.